<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04106557</url>
  </required_header>
  <id_info>
    <org_study_id>OV101-19-001</org_study_id>
    <nct_id>NCT04106557</nct_id>
  </id_info>
  <brief_title>A Study of OV101 in Individuals With Angelman Syndrome (AS)</brief_title>
  <acronym>NEPTUNE</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ovid Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ovid Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of oral OV101 (gaboxadol) in
      pediatric subjects with Angelman syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Participant/Care Giver and Investigator/Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Global Impressions- Improvement in Angelman Syndrome (CGI-I-AS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical Global Impressions-Improvement-Angelman Syndrome (CGI-I-AS) - Scale of 1-7 reflects a spectrum where 1 is most improved, 4 is no change, and 7 is most worsened.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Primary Disease or Condition Being Studied: Angelman Syndrome (AS)</condition>
  <arm_group>
    <arm_group_label>OV101 once daily (weight-based dosing) Other Name:Gaboxadol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OV101 (gaboxadol), oral, provided once daily at bedtime for 12 week duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo,oral, provided once daily at bedtime for 12 week duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gaboxadol</intervention_name>
    <description>OV101 versus placebo once daily at bedtime for 12 weeks</description>
    <arm_group_label>OV101 once daily (weight-based dosing) Other Name:Gaboxadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules to OV101 capsules.</description>
    <arm_group_label>Placebo once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female and 2 to 12 years old (inclusive) at the time of informed consent

          -  Confirmed molecular diagnosis of AS

          -  Has a CGI-S-AS score of 3 or more at baseline.

          -  Meets the following age-appropriate body weight criterion:

               1. Subjects 2 to 3 years old must have a minimum body weight of 9 kg.

               2. Subjects 4 years and older must be between 17 kg and 64 kg (inclusive).

          -  Stable concomitant mediations for at least 4 weeks before study start

        Exclusion Criteria:

          -  Any condition that would limit study participation

          -  Clinically significant lab or vital sign abnormalities at the time of screening

          -  Poorly controlled seizures (weekly seizures of any frequency with a duration more than
             3 minutes, weekly seizures occurring more than 3 times per week, each with a duration
             of less than 3 minutes, or as defined by investigator assessment)

          -  Use of prescription medications for sleep, minocycline, or levodopa within the 4 weeks
             prior to Day 1 or during the study. Benzodiazepines chronically administered for
             seizure control are permitted.

          -  Cannot comply with protocol study assessments during screening or caregiver unable to
             comply with study requirements.

          -  Enrolled in any clinical trial or used any investigational agent within the 30 days
             before screening or concurrently with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ovid - Neptune US Clinical Research Referral Network Media, PA</last_name>
    <phone>1-855-235-3138</phone>
    <email>clinicaltrialsinquiry@ovidrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network angelmanstudy.com</last_name>
      <phone>855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network angelmanstudy.com</last_name>
      <phone>855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network angelmanstudy.com</last_name>
      <phone>855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network Angelmanstudy.com</last_name>
      <phone>855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Lexington</city>
        <state>Massachusetts</state>
        <zip>02421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network angelmanstudy.com</last_name>
      <phone>855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Carrboro</city>
        <state>North Carolina</state>
        <zip>27510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network angelmanstudy.com</last_name>
      <phone>855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network Angelmanstudy.com</last_name>
      <phone>855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Media</city>
        <state>Pennsylvania</state>
        <zip>19063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network angelmanstudy.com</last_name>
      <phone>855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network Angelmanstudy.com</last_name>
      <phone>855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network Angelmanstudy.com</last_name>
      <phone>855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network angelmanstudy.com</last_name>
      <phone>+1-855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network Angelmanstudy.com</last_name>
      <phone>+1-855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network Angelmanstudy.com</last_name>
      <phone>+1-855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network angelmanstudy.com</last_name>
      <phone>+1-855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ovid Therapeutics Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3012CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ovid - Neptune US Clinical Research Referral Network Angelmanstudy.com</last_name>
      <phone>+1-855-235-3138</phone>
      <email>clinicaltrialsinquiry@ovidrx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angelman Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaboxadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

